- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2022-11-30
2024-02-26
2024-05-31
120
NCT06291779
Seoul National University Hospital
Seoul National University Hospital
OBSERVATIONAL
Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine
* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. * It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.
* CubeBio and Seoul National University Bundang Hospital signed a joint technology development agreement to compare the analytical performance of existing analytical methods and purine metabolite analysis reagents developed by CubeBio. * Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites. * Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis. * This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2023-01-14 | N/A | 2024-02-26 |
2024-02-26 | N/A | 2024-03-04 |
2024-03-04 | N/A | 2024-02 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| : Pancreatic cancer group scheduled for curative surgery for pancreatic cancer | DEVICE: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
|
| : Control group group included healthy individuals as well as patients with benign diseases | DEVICE: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Urine | mean concentration of purine metabolites in urine | 1 day |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: MeeYoung Kang, M.D. Phone Number: 82-10-5575-8881 Email: rime0317@gmail.com |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
1
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
